In all patients, the percentage reductions of the PLR and CRP were positively correlated with that of the PASI at week 52 (Table 4), indicating that the PLR and CRP might act as biomarkers reflecting treatment response to TNF-α inhibitors in psoriasis. The gene discussed is TNF; the disease is psoriasis.